Gheysens Nicolas
Known title: DirectorCIK: 0001993116
Associated companies
Transaction History
| CNXC | ▲ Buy | Grant | 3,873 | $0 | 3/25/2025 | View on chart |
| CNXC | ▲ Buy | Grant | 2,780 | $0 | 3/21/2024 | View on chart |
| CNXC | ▲ Buy | Grant | 1,173 | $0 | 9/25/2023 | View on chart |
| CNXC | ▲ Buy | Grant | 3,873 | $0 | 3/25/2025 | View on chart |
| CNXC | ▲ Buy | Grant | 2,780 | $0 | 3/21/2024 | View on chart |
| CNXC | ▲ Buy | Grant | 1,173 | $0 | 9/25/2023 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
CNXC Faces Scrutiny Over Loss Guidance and Dividend Policy
Recent articles question whether Concentrix's loss-making guidance and ongoing dividend payouts are changing its investment case. The stock is also being highlighted in broader business services industry outlooks alongside peers like ABM and Sodexo. With the share price trading near its 52-week low, these reports add context to the current valuation debate.
CNXC Faces Scrutiny Over Loss Guidance and Dividend Policy. Recent articles question whether Concentrix's loss-making guidance and ongoing dividend payouts are changing its investment case. The stock is also being highlighted in broader business services industry outlooks alongside peers like ABM and Sodexo. With the share price trading near its 52-week low, these reports add context to the current valuation debate.